Navigation Links
Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
Date:3/13/2008

aceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal(TM) for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera(TM) for the treatment of Gaucher disease. The Company recently completed Phase I clinical trials of AT2220 for the treatment of Pompe disease.

Forward-Looking Statements

Amicus cautions you that statements included in this press release that are not a description of historical facts are "forward-looking statements" within the meaning of Section 21E of the Private Securities Litigation Reform Act of 1995. Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "should" and "could," and similar expressions or words identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. The inclusion of forward-looking statements should not be regarded as a representation by Amicus that any of its plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong. They can be affected by inaccurate assumptions Amicus might make or by known or unknown risks and uncertainties. For example, with respect to statements regarding the potential progress and results of clinical trials, actual results may differ materially from those set forth in this release due to the risks and uncertaintie
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
11. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 26, 2014 PMG Research, Inc. ... Research is a network of sites that provide clinical research ... 2 million patient lives through its partnerships with large physician ... 11 hub site locations in the Southeastern United States and ... of the board will be held by: Dr. ...
(Date:11/26/2014)... Continuing its award-winning streak, Nerium International, the ... Awards for outstanding creative achievement by its marketing and ... the organization’s top honor, in the Branding category for ... April of this year. The event showcased top speakers ... was awarded a Gold MarCom Award in the Special ...
(Date:11/26/2014)... 26, 2014 SoundConnect , an ... proud to announce that Darren Suders has joined the ... Darren will drive the partner program through ... , Darren brings more than 10-years of ... roles in channel operations, from policy development, to partner ...
(Date:11/26/2014)... -- Bio-Techne Corporation (NASDAQ: TECH ) announced ... to serve in a newly created position of Senior ... will be responsible for managing the operations of Bio-Techne,s ... acquired in July 2014 and the recently acquired CyVek ... -based ProteinSimple develops and commercializes proprietary systems and consumables ...
Breaking Biology Technology:PMG Research Names Medical Advisory Board 2PMG Research Names Medical Advisory Board 3Nerium International™ Wins One Platinum, Two Gold MarCom Awards 2SoundConnect Appoints Director of Channel Development & Sales 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 3
... be participating in the Barclays Capital 2010 Global Healthcare Conference in Miami, Fla. , on March 23, 2010 , at 8:30 a.m. Eastern Time .   , ... , ... ... ...
... for life science researchers, has selected Biodiagnostics as its new distributor of IPA® in Greece , Turkey ... systems at the core of life science research. , ... ... ...
... patient cases using magnetic resonance-guided heat (laser interstitial ... cancer recurrence after surgical removal of the prostate ... of Interventional Radiology,s 35th Annual Scientific Meeting in ... salvage radiation treatment and are often presented with ...
Cached Biology Technology:Zimmer Holdings to Present at Barclays Capital 2010 Global Healthcare Conference 2Ingenuity Systems Announces New Distributor for Greece, Turkey and the Balkans 2Ingenuity Systems Announces New Distributor for Greece, Turkey and the Balkans 3The hot -- and cold -- interventional radiology treatments for recurrent prostate cancer 2The hot -- and cold -- interventional radiology treatments for recurrent prostate cancer 3
(Date:11/4/2014)... marketing directed at children on the interior and ... the majority of black, middle-income and rural communities ... Authored by Arizona State University researcher Punam Ohri-Vachaspati ... to examine the use of child-directed marketing on ... and its relationship to demographics. It adds to ...
(Date:11/4/2014)... – (Nov. 4, 2014) – A majority of Madagascar,s ... that could have serious consequences for the rainforests they ... shows the positive impacts lemurs can have on rainforest ... their disappearance could have on the region,s rich biodiversity. ... have fruits eaten by lemurs. Lemurs in turn ...
(Date:11/3/2014)... , Nov. 3, 2014 Research and Markets ... "Cell Therapy - Technologies, Markets and Companies" to their ... therapy technologies and methods, which have already started to play ... cell transplantation is replacing the old fashioned bone marrow transplants. ... therapy is bound to become a part of medical practice. ...
Breaking Biology News(10 mins):Fast food marketing for children disproportionately affects certain communities 2Fast food marketing for children disproportionately affects certain communities 3Gardeners of Madagascar rainforest at risk 2Gardeners of Madagascar rainforest at risk 3Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3
... to study addicted,smokers, a new drug that attaches ... implicated in nicotine addiction ,may help studies ... and schizophrenia.,Developed by UC Irvine Transdisciplinary Tobacco Use ... selective binding agent,that identifies specific areas of the ...
... may be precipitated by a "traffic jam" within neurons ... and structures in the cells, according to new studies ... models of Alzheimer's disease and in human brain samples ... breakdown in neurons that appears to prevent the normal ...
... Scientists at Joslin Diabetes Center have discovered one reason why ... developing type 2 diabetes later in life. In studies of ... pancreas's ability to later secrete enough insulin in response to ... don't have delivery of enough nutrients from the mother to ...
Cached Biology News:Drug That 'Tags' Decision-making Areas Of The Brain May Aid 2Neuronal 'traffic jam' marks early Alzheimer's disease 2Neuronal 'traffic jam' marks early Alzheimer's disease 3Neuronal 'traffic jam' marks early Alzheimer's disease 4Poor prenatal nutrition permanently damages function of insulin-producing cells in the pancreas 2Poor prenatal nutrition permanently damages function of insulin-producing cells in the pancreas 3Poor prenatal nutrition permanently damages function of insulin-producing cells in the pancreas 4
The new Silencer siRNA Starter Kit is perfect for researchers new to RNAi. It provides all of the reagents, protocols, and instructions necessary to get underway with siRNA transfection and ensure su...
... protein Vtg in plasma from juvenile or male ... endocrine disrupting chemicals (EDCs) with estrogenic effects in ... screening test for the estrogenic effects of EDCs ... is a double-antibody immunometric (sandwich) EIA for analyzing ...
... is a 17 amino acid synthetic peptide whose sequence is from ... to carboxy terminus): C - N(217) - Q - P ... A - T - P - N - Y - T ... be used for neutralization and control experiments with the polyclonal antibody ...
... for which no antibody exists? Having difficulty generating ... a variety of pharmaceutical, biotech and academic researchers ... technology and expertise in antibody generation to work ... RabMAb development technology , High affinity and high ...
Biology Products: